Landmark biomarker and prevention studies, and hypothetical models of preclinical neurodegenerative diseases have been reported in The Lancet and The Lancet Neurology over the past decade. Reflecting our commitment to support this crucial area of neurological research, this Summit will provide a timely update on the latest advances and challenges in this area, with an emphasis on prevention.

The Summit will also provide a forum for discussion of the ethical and regulatory issues that these advances will bring about in research settings and clinical practice.

The programme will cover these topics:

• Genetics, cellular pathways, and neuronal vulnerability
• Biomarkers and early diagnosis
• Prevention through therapeutics
• Ethical and regulatory considerations

This event is sponsored by the UK Dementia Research Institute